ABMD - Abiomed completes post-approval reports for FDA for Impella heart pumps

• The US FDA has accepted Abiomed's ( NASDAQ: ABMD ) post-approval study reports related to the pre-market approvals for its Impella heart pumps.
• The pumps are used for cardiogenic shock, high-risk percutaneous coronary intervention, post-cardiotomy cardiogenic shock, cardiogenic shock in the setting of myocarditis or cardiomyopathy, and right heart failure.
• Abiomed ( ABMD ) completed five post-approval studies for Impella over since its initial pre-market approvals were received.
• Seeking Alpha's Quant Rating views Abiomed ( ABMD ) as a hold with high marks for profitability and revisions .

For further details see: